Abstract
Based on the survival benefits and favorable safety profile seen in the phase III CheckMate 141 trial,1 nivolumab was approved in Europe in 2017 for patients (pts) with R/M SCCHN who progressed on, or within 6 months (mos) after platinum-based therapy. Data from a large real-world population can provide important insight. ProNiHN was conducted to describe the characteristics of SCCHN pts treated with nivolumab in France and to assess its efficacy and safety.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
